OCGN Quote, Financials, Valuation and Earnings

Anavex Life Sciences Corp. has a net margin of -1144.46% compared to Ocugen, Inc.'s net margin of --. Ocugen, Inc.'s return on equity of -345.08% beat Anavex Life Sciences Corp.'s return on equity of -44.87%.

Ocugen, Inc. has a consensus price target of $9.00, signalling upside risk potential of 576.69%. On the other hand Anavex Life Sciences Corp. has an analysts' consensus of $22.00 which suggests that it could grow by 436.59%. Given that Ocugen, Inc. has higher upside potential than Anavex Life Sciences Corp., analysts believe Ocugen, Inc. is more attractive than Anavex Life Sciences Corp..

Ocugen, Inc. has a beta of 3.493, which suggesting that the stock is 249.3% more volatile than S&P 500. In comparison Anavex Life Sciences Corp. has a beta of 1.212, suggesting its more volatile than the S&P 500 by 21.178%.

Ocugen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anavex Life Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen, Inc. pays -- of its earnings as a dividend. Anavex Life Sciences Corp. pays out -- of its earnings as a dividend.

Ocugen, Inc. quarterly revenues are $1.8M, which are larger than Anavex Life Sciences Corp. quarterly revenues of --. Ocugen, Inc.'s net income of -$20.1M is lower than Anavex Life Sciences Corp.'s net income of -$9.8M. Notably, Ocugen, Inc.'s price-to-earnings ratio is -- while Anavex Life Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen, Inc. is 73.00x versus -- for Anavex Life Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Belite Bio, Inc. has a net margin of -1144.46% compared to Ocugen, Inc.'s net margin of --. Ocugen, Inc.'s return on equity of -345.08% beat Belite Bio, Inc.'s return on equity of -37.13%.

Ocugen, Inc. has a consensus price target of $9.00, signalling upside risk potential of 576.69%. On the other hand Belite Bio, Inc. has an analysts' consensus of $186.50 which suggests that it could grow by 2.27%. Given that Ocugen, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Ocugen, Inc. is more attractive than Belite Bio, Inc..

Ocugen, Inc. has a beta of 3.493, which suggesting that the stock is 249.3% more volatile than S&P 500. In comparison Belite Bio, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ocugen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Belite Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen, Inc. pays -- of its earnings as a dividend. Belite Bio, Inc. pays out -- of its earnings as a dividend.

Ocugen, Inc. quarterly revenues are $1.8M, which are larger than Belite Bio, Inc. quarterly revenues of --. Ocugen, Inc.'s net income of -$20.1M is higher than Belite Bio, Inc.'s net income of -$21.7M. Notably, Ocugen, Inc.'s price-to-earnings ratio is -- while Belite Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen, Inc. is 73.00x versus -- for Belite Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CorMedix, Inc. has a net margin of -1144.46% compared to Ocugen, Inc.'s net margin of 49.9%. Ocugen, Inc.'s return on equity of -345.08% beat CorMedix, Inc.'s return on equity of 95.25%.

Ocugen, Inc. has a consensus price target of $9.00, signalling upside risk potential of 576.69%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 93.2%. Given that Ocugen, Inc. has higher upside potential than CorMedix, Inc., analysts believe Ocugen, Inc. is more attractive than CorMedix, Inc..

Ocugen, Inc. has a beta of 3.493, which suggesting that the stock is 249.3% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.

Ocugen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Ocugen, Inc. quarterly revenues are $1.8M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Ocugen, Inc.'s net income of -$20.1M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Ocugen, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen, Inc. is 73.00x versus 2.59x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Verastem, Inc. has a net margin of -1144.46% compared to Ocugen, Inc.'s net margin of -876.34%. Ocugen, Inc.'s return on equity of -345.08% beat Verastem, Inc.'s return on equity of -1773.4%.

Ocugen, Inc. has a consensus price target of $9.00, signalling upside risk potential of 576.69%. On the other hand Verastem, Inc. has an analysts' consensus of $16.63 which suggests that it could grow by 149.25%. Given that Ocugen, Inc. has higher upside potential than Verastem, Inc., analysts believe Ocugen, Inc. is more attractive than Verastem, Inc..

Ocugen, Inc. has a beta of 3.493, which suggesting that the stock is 249.3% more volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.56%.

Ocugen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.

Ocugen, Inc. quarterly revenues are $1.8M, which are smaller than Verastem, Inc. quarterly revenues of $11.2M. Ocugen, Inc.'s net income of -$20.1M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Ocugen, Inc.'s price-to-earnings ratio is -- while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen, Inc. is 73.00x versus 31.17x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.